In this episode, David Flores talks with Sherry Rais of Enthea to discuss Enthea’s very unique objective of helping employers optimize happiness and health within their workplace by integrating ketamine therapy as an add-on to their existing employee health benefit programs.
In this week’s episode of The Spotlight Roundup, we check in with the Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
In this episode, we dive into the transformational testimonial of Cesar Maren’s experience with microdosing. Once a CNN TV producer, and now a full time advocate for the power of intentional microdosing, Cesar shares with us his journey how it helped transform his life.
Kevin Colley, a former professional hockey player with over a decade of experience, including a stint with the NHL’s New York Islanders, embarked on a profound journey earlier this year. Invited by fellow retired NHL player Riley Cote, Kevin participated in a transformative psychedelic-focused retreat as a patient of WAKE’s clinical program in Jamaica.
Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!
On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.
Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.
In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.
Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/
CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/
MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#FieldTripHealth #Cybin #Mydecine
May 12, 2021- This week’s Psychedelic Business News Round Up’s…
What’s up psychedelic investors! In this episode, we’ll be comparing the top 10 psychedelic stocks’ financials.
Will look at the 4 most important financial stats for each of the top 10 companies in the Psychedelic Medicines field, selected by market cap.
First, we will look at the market cap, because that tells us how valuable the market judges the company to be, and it tells us how easily a company can raise capital.
Next, we will look at cash on hand.
Third, we will look at how much a company is spending.
Finally, we will look at revenue where applicable
All figures are in American dollars.
So which stocks we’ll be comparing, you may ask? We’ll look at:
– Atai Life Sciences ( NASDAQ: ATAI)
– Compass Pathways (NASDAQ: CMPS)
-MindMed (NASDAQ: MNMD), ( NEO: MMED)
– Cybin Inc (NYSE: CYBN)
– Numinus Wellneass (TSX: NUMI) (OTC: LKYSF)
– Revive Therapeutics (CN: RVV) (OTC: RVVTF)
– Small Pharma ( TSX: DMT)
-Mydecine (OTC: MYCOF) (NEO: MYCO)
– Red Light Holland ( CSE: TRIP) (OTC: TRUFF)
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #ATAISTOCK #PsychedelicStocks
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
